HER2-Negative Breast Cancer

Sponsored by: GlobalData

Focused on:

  • Global Drug Forecast
  • Breast Cancer

Date: 27 February

Days to go: 7

Time: 3PM London/10AM New York

Global Drug Forecast and Market Analysis to 2028

Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancers in the world and the most common cancer in women worldwide. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate above 90%. However, in the later stages of the disease, survival rapidly decreases. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+(grouped together as hormone receptor-positive [HR+]), and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). HR+ breast cancer accounts for approximately 70% of all breast cancer cases, and is most commonly diagnosed in older patients. It is generally considered less aggressive, as it is usually low-grade, and the patient prognosis is relatively good. TNBC accounts for approximately 10–15% of all breast cancer cases. Patients with TNBC tumors have a relatively poor prognosis, and are more likely to carry a BRCA mutation. Historically HR+ breast cancer has typically been treated with hormone therapies which act as the cornerstone of treatment for patients with this disease while physicians have typically relied on chemotherapy for patients with triple negative breast cancer. This has significantly changed in the last 5 years.

Improved patient outcomes have been achieved by diagnosing cancer at the earliest stage when a tumor is resectable and curative measures can be directed to a specific site in the body. However, once the cancer metastasizes, 5 year survival rates plummet to below 25%. Significant improvements in progression free survival and overall survival have arrived with the introduction of targeted therapies and immunotherapies in the last 5 years for patients with advanced disease. Specifically, the introduction of CDK4/6 inhibitors in combination with hormone therapy (Ibrance, Kisqali and Verzenio) have become the standard of care in metastatic HR+ breast cancer. Recently approved agents include Piqray, which is positioned to treat patients who have relapsed on first line therapies and harbor a PI3KCA mutation. Further innovation in the pipeline means that commonly used endocrine therapies are being reformulated into oral tablets, providing convenience for the patient and increasing the maximum feasible dose which can be administered. The introduction of such agents counters unmet needs in the HR+ setting highlighted by physicians during primary research conducted by GlobalData. With regards to the treatment of TNBC, the introduction of PARP inhibitors, and more recently a checkpoint inhibitor, provide efficacious personalized therapies for a patient group with a huge unmet clinical need. Phase III development offers further options for this patient population and the likelihood that targeted therapies will gain label expansions and be utilized in earlier lines of therapy.

In this webinar Adam Pearson, PhD, Healthcare Analyst at GlobalData, will present the drug forecast and market analysis to 2028, drawing on key insights from GlobalData’s recently published report, HER2-Negative Breast Cancer: Global Drug Forecast and Market Analysis to 2028. The current treatment options and drug pipeline for HER2-Negative breast cancer will be covered, including a discussion on GlobalData’s sales forecasts for the most impactful HER2-Negative breast cancer therapies. The webinar will cover insights from various key opinion leaders (KOLs) on the current treatment options, pipeline drugs, the unmet needs, and the most promising R&D strategies. Fern Barkalow, PhD, Senior Director of Oncology and Hematology at GlobalData will moderate the Q&A session following the presentation.

Presented by

Adam Pearson,

Oncology and Hematology Analyst

Adam Pearson, PhD, is a Oncology and Hematology Analyst at GlobalData in London. He offers in-depth market intelligence and data interpretation within the oncology pharmaceuticals sector. Adam completed his Cancer Research UK funded PhD in Molecular Cancer Studies at the University of Manchester where he studied the mechanisms whereby ERK5 regulates transcription, with a particular interest in how ERK5 promotes the development of resistance in HER2-positive breast cancer. Prior to this, he received an MSc in Cancer Biology from University College London and his BSc in Biomedical Sciences from the University of Manchester. He has also worked as a scientist in a Molecular Pathology Lab as part of the Imperial College NHS Healthcare Trust at Hammersmith Hospital.

Fern Barkalow,

Senior Director of Oncology and Hematology

Fern Barkalow, PhD, is the Senior Director of Oncology and Hematology at GlobalData in Boston. Fern has over 20 years of experience in the biopharmaceutical industry, as well as a research background in molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern then joined the database group at Incyte Pharmaceuticals where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then moved into the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs. Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine andDentistry of New Jersey and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women’s Hospital.

Key Learning Objectives

  • Learn how the HER2-Negative breast cancer market dynamics are expected to change between 2018 and 2028 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and China)
  • Gain in-depth insight about the late-stage HER2-Negative breast cancer pipeline, including the products that are expected to dominate the market and the key drivers behind these.
  • Understand the unmet needs that key opinion leaders (KOLs) have identified in the HER2-Negative breast cancer treatment space and an analysis on whether the current pipeline will meet these needs.
  • Learn about some of the key R&D strategies, growth drivers, and barriers in the HER2-Negative breast cancer market across the 8MM.


  • Managers/Senior Managers
  • Associate Directors
  • Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers